Daly Richard J sold (to issuer) $8.5M of CPRX
Daly Richard J (President and CEO) sold (to issuer) 271,266 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($8.54M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s $8.54M sale to the issuer at $31.50/share, with holdings reduced to 0 shares. The filing does not include new guidance, trial results, approvals, or enforcement actions.
Market read
Primarily a positioning/sentiment datapoint; likely low incremental trading value versus company fundamentals.
What to watch
No 10b5-1 plan is indicated, but the filing still does not explain motivation; traders should avoid over-weighting insider sales without accompanying fundamental news.
Background
The article is a SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals, Inc. (CPRX).
Ticker impact
Catalyst Pharmaceuticals CEO Richard J. Daly sold 271,266 shares to the issuer for $8.54M at $31.50/share, leaving 0 shares.
Likely limited near-term impact; any effect is more about signaling/positioning than fundamentals.
The filing discloses a specific insider transaction size and price, but provides no new company performance, guidance, or external event.
Market effects
Minimal read-through for biotech sector; this is an issuer-related insider sale with no disclosed clinical or regulatory update.
None.
None.
Counterpoint
Because the sale is to the issuer (often tied to buyback mechanics), it may be routine and not a bearish signal about prospects.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
CPRX, subject of the Form 4 insider transaction disclosure.
- insiderRichard J. Daly
President and CEO who sold 271,266 shares to the issuer.